Cipher Pharmaceuticals: Buy, Sell or Hold?

Leede Financial says Cipher Pharmaceuticals’ (Cipher Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:CPH) legal win against Sun Pharmaceutical strengthens its balance sheet and could refocus attention on its Absorica opportunity.

Analyst Douglas Loe maintained his “Buy” rating and $19.50 target on Cipher.

The Ontario-based specialty pharmaceutical company said a New York court decision tied to Absorica will result in a damages award of US$3.05-million, or about $4.2-million, plus potential recovery of 80% of arbitration-specific legal costs.

In his  Sept. 2 update, Loe said the cash award is not a major driver of his valuation, but it should reduce financial risk and give Cipher more flexibility to support future product licensing deals.

The analyst said the ruling is also positive because it gives Cipher a 15% royalty on Sun’s Canadian Absorica LD sales through fiscal 2040, retroactive from fiscal Q1 2026 to fiscal Q3 2026.

Loe expects the Canadian royalty revenue to be positive but modest, saying he has not yet added it to his model.

More importantly, he said the arbitration outcome shifts attention back to Cipher’s opportunity to acquire U.S. marketing rights for Absorica by fiscal Q4 2026.

Loe said Cipher could market Absorica more aggressively than Sun has in recent years, potentially using the U.S. dermatology infrastructure it gained through the ParaPro and Natroba acquisition.

He said Natroba remains the main driver of his Cipher revenue forecast, with Canadian Epuris sales close behind. He continues to expect Health Canada’s review of Natroba to conclude favourably, allowing a Canadian launch in the first half of fiscal 2027.

Loe’s valuation is based on multiples of his fiscal 2027 adjusted EBITDA and EPS forecasts of US$31.6-million and 75 cents, respectively.

The analyst expects Cipher to generate Adjusted EBITDA of US$29.9-million on revenue of US$51.3-million in fiscal 2026, improving to Adjusted EBITDA of US$31.6-million on revenue of US$54.2-million in fiscal 2027.

 

-30-

Tagged with: cph
Tara Whittet

Tara Whittet is Senior Sales Manager at Cantech Letter.

Recent Posts

Can you make money with Metatek-Group stock?

Metatek-Group’s (Metatek-Group Stock Quote, Chart, News, Analysts, Financials TSX:MTEK) strong sequential revenue growth and expectations for a further improvement in… [Read More]

3 hours ago

Ascend Wellness Holdings: Buy, Sell or Hold?

Ascend Wellness Holdings’ (Ascend Wellness Holdings Stock Quote, Chart, News, Analysts, Financials CSE:AAWH.U) return to year-over-year revenue growth and improving… [Read More]

3 hours ago

RBC raises price target on Tidewater Renewables to $31.00

RBC Capital Markets analyst Maurice Choy raised his target on Tidewater Renewables (Tidewater Renewables Stock Quote, Chart, News, Analysts, Financials… [Read More]

4 hours ago

Apotex Health: this analyst just raised his price target

RBC Capital Markets analyst Douglas Miehm raised his target for Apotex Health (Apotex Health Stock Quote, Chart, News, Analysts, Financials… [Read More]

4 hours ago

Magellan Aerospace: Buy, Sell or Hold?

Magellan Aerospace’s (Magellan Aerospace Corp. Stock Quote, Chart, News, Analysts, Financials TSX:MAL) stronger-than-expected third-quarter results and potential opportunities from increased… [Read More]

4 hours ago

Is Cargojet (TSX:CJT) a buy right now?

Cargojet's (Cargojet Stock Quote, Chart, News, Analysts, Financials TSX:CJT) stronger-than-expected third-quarter results and ability to maintain margins despite higher fuel… [Read More]

4 hours ago